Time to be blunt: Substance use in cystic fibrosis

Abstract

AbstractBackgroundAs the population of people with cystic fibrosis (pwCF) continues to age, attention is shifting towards addressing the unique challenges teenagers and adults face, including substance use. Changing attitudes and legality regarding marijuana and cannabidiol (CBD) may influence their use among pwCF, but data on the rate of use, reasons for use, and administration methods are lacking.ObjectiveInvestigate marijuana, CBD, e‐cigarette, and cigarette usage among pwCF and explore differences in demographics, disease severity, and cystic fibrosis transmembrane receptor (CFTR) modulator use between recent users and nonusers.MethodsThis cross‐sectional study used a one‐time electronic survey to assess marijuana, CBD, e‐cigarette, and cigarette use in pwCF aged >13 years. Demographic and clinical characteristics were compared between recent users and nonusers. The association between recent substance use and CFTR modulator use was analyzed using logistic regressions.ResultsAmong 226 participants, 29% used marijuana, 22% used CBD, 27% used e‐cigarettes, and 22% used cigarettes in the last 12 months. Users of all substances were more likely to be college‐educated or aged 29‐39 years than nonusers. E‐cigarette users were 2.9 times more likely to use CFTR modulators (95% confidence interval [95% CI]: 0.98–11.00, p = .08) and marijuana users were 2.5 times more likely to use CFTR modulators compared to nonusers, adjusted for confounders. CBD, e‐cigarettes, and cigarettes users were more likely to have an abnormal mental health screen compared to nonusers. A high proportion of never‐users of marijuana and CBD expressed interest in using.ConclusionSubstance use is more prevalent among pwCF than previously reported and needs to be addressed by healthcare providers.